Live Breaking News & Updates on Yasushi Goto

Stay updated with breaking news from Yasushi goto. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting

Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical. ....

United States , San Carlos , Mridula George , Ryoichi Naito , Rebecca Hassoun , Aziz Zaanan , Sarah Lee , Sherene Loi , Marla Lipsyc Sharf , Yoshiaki Nakamura , Glenn Hanna , Adanma Ayanambakkam , Eric Lander , Michael Lapelusa , Clinical Laboratory Improvement Amendments , American Society Of Clinical Oncology , Natera Inc , Clinical Oncology , Annual Meeting , Breast Cancer , Testicular Cancer , Prognostic Biomarker , Detect Minimal Residual Disease , Urothelial Cancer , Esophageal Cancer , Recurrence Free Survival ,

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC

Combination treatment consisting of datopotamab deruxtecan and pembrolizumab with or without platinum-based chemotherapy generated responses as first- or second-line treatment for patients with advanced or metastatic non–small cell lung cancer. ....

National Cancer Center Hospital , Yasushi Goto , Tolerability Remains Steady , Asco Annual Meeting ,

Dr Goto on Datopotamab Deruxtecan Plus Pembrolizumab and Chemotherapy in Advanced NSCLC

Yasushi Goto, MD, discusses primary efficacy findings from the phase 1 TROPION-Lung02 trial of datopotamab deruxtecan plus pembrolizumab with or without platinum-based chemotherapy in patients with advanced non–small cell lung cancer. ....

National Cancer Center Hospital , Datopotamab Deruxtecan Plus Pembrolizumab , Yasushi Goto , Tropion Lung02 Trial , Patients With Advanced Non Small Cell Lung Cancer ,

Daiichi Sankyo : Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial (238.4KB

Press Release

Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase. | June 5, 2023 ....

United States , Cristian Massacesi , Mark Rutstein , Daiichi Sankyo , National Cancer Center Hospital , Sarah Cannon Research Institute , Oncology Clinical Development , American Society Of Clinical Oncology Annual Meeting , Merck Co Inc , Sapporo Medical University , Division Of Internal Medicine , Press Release , Advanced Non Small Cell Lung Cancer , Basking Ridge , American Society , Clinical Oncology Annual Meeting , Yasushi Goto , Internal Medicine , Thoracic Oncology , Global Head , Chief Medical Officer , Chief Development Officer , Efficacy Results , Astrazeneca Collaboration , Datopotamab Deruxtecan , Sarah Cannon Research ,

Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial

In previously untreated patients, Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus pembrolizumab with or without platinum chemotherapy demonstrated objective response rates of 57%. | June 5, 2023 ....

United States , Mark Rutstein , Ann Onc , Cristian Massacesi , Daiichi Sankyo , Sarah Cannon Research Institute , American Cancer Society , Merck Co Inc , Sapporo Medical University , American Society Of Clinical Oncology Annual Meeting , International Agency For Research On Cancer , Sustainable Development Of Society , National Cancer Center Hospital , Innovative Global Healthcare Company , Division Of Internal Medicine , Oncology Clinical Development , World Health Organization , American Society , Clinical Oncology Annual Meeting , Yasushi Goto , Internal Medicine , Thoracic Oncology , Global Head , Chief Medical Officer , Chief Development Officer , Astrazeneca Collaboration ,